Analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO) to announce $27.15 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Harvard Bioscience's earnings. The highest sales estimate is $27.30 million and the lowest is $27.00 million. Harvard Bioscience posted sales of $30.97 million during the same quarter last year, which suggests a negative year over year growth rate of 12.3%. The company is scheduled to issue its next earnings results on Wednesday, February 24th.

According to Zacks, analysts expect that Harvard Bioscience will report full-year sales of $98.30 million for the current year, with estimates ranging from $98.10 million to $98.50 million. For the next year, analysts expect that the business will post sales of $107.25 million, with estimates ranging from $106.00 million to $108.50 million. Zacks' sales calculations are a mean average based on a survey of research firms that that provide coverage for Harvard Bioscience.

Several equities research analysts have commented on HBIO shares. KeyCorp started coverage on Harvard Bioscience in a research note on Monday, November 9th. They set an "overweight" rating for the company. Northland Securities started coverage on Harvard Bioscience in a research note on Wednesday, December 9th. They set an "outperform" rating for the company. Finally, Benchmark upgraded Harvard Bioscience from a "speculative buy" rating to a "buy" rating in a research note on Thursday, January 7th. One equities research analyst has rated the stock with a sell rating and three have given a buy rating to the stock. Harvard Bioscience has an average rating of "Buy" and an average price target of $3.38.

NASDAQ:HBIO opened at $4.69 on Friday. Harvard Bioscience has a 12 month low of $1.39 and a 12 month high of $5.21. The stock has a 50 day moving average of $4.42 and a two-hundred day moving average of $3.76. The company has a current ratio of 2.05, a quick ratio of 0.98 and a debt-to-equity ratio of 0.53. The firm has a market cap of $182.80 million, a P/E ratio of -26.06 and a beta of 1.73.

Several hedge funds have recently bought and sold shares of HBIO. BNP Paribas Arbitrage SA grew its position in shares of Harvard Bioscience by 518.8% in the third quarter. BNP Paribas Arbitrage SA now owns 8,743 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 7,330 shares in the last quarter. Citigroup Inc. grew its position in shares of Harvard Bioscience by 290.3% in the fourth quarter. Citigroup Inc. now owns 7,177 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 5,338 shares in the last quarter. Sowell Financial Services LLC purchased a new stake in shares of Harvard Bioscience in the fourth quarter valued at approximately $40,000. Squarepoint Ops LLC purchased a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $75,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $143,000. Institutional investors and hedge funds own 64.87% of the company's stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Further Reading: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

20 Stocks Analysts Can't Stop Upgrading

As you know, a single upgrade from a broker probably won't be a major game-changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?

If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.

It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.

View the "20 Stocks Analysts Can't Stop Upgrading".



Source link